Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Vanderbilt
mi
from
Nashville, TN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UT Southwestern
mi
from
Dallas, TX
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UT Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Northwest Medical Specialties
mi
from
Tacoma, WA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
San Diego Pacific Oncology and Hematology Associates
mi
from
Encinitas, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
San Diego Pacific Oncology and Hematology Associates
mi
from
Encinitas, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Southern California (USC)
mi
from
Los Angeles, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Southern California (USC)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Parkview Research Center
mi
from
Fort Wayne, IN
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Parkview Research Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Greenville Health System, Institute for Translational Oncology Research
mi
from
Greenville, SC
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Greenville Health System, Institute for Translational Oncology Research
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Safety and Tolerability Study in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Pinnacle Oncology Hematology
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated:  12/31/1969
The University of California Irvine
mi
from
Orange, CA
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated: 12/31/1969
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated:  12/31/1969
University of Maryland
mi
from
Baltimore, MD
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated: 12/31/1969
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated:  12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated: 12/31/1969
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Ponatinib in Advanced NSCLC w/ RET Translocations
A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology
Status: Enrolling
Updated:  12/31/1969
Northwest Cancer Specialists Compass Oncology -BKM
mi
from
Portland, OR
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology
Status: Enrolling
Updated: 12/31/1969
Northwest Cancer Specialists Compass Oncology -BKM
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Toronto,
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Toronto,
Click here to add this to my saved trials
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology
Status: Enrolling
Updated:  12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer
A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology
Status: Enrolling
Updated: 12/31/1969
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Providence Alaska Medical Center
mi
from
Anchorage, AK
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
McKee Medical Center
mi
from
Loveland, CO
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
mi
from
Hollywood, FL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Baptist Medical Center South
mi
from
Jacksonville, FL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Baptist Medical Center South
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
UF Cancer Center at Orlando Health
mi
from
Orlando, FL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
UF Cancer Center at Orlando Health
mi
from
Orlando, FL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology-Palatka
mi
from
Palatka, FL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology-Palatka
mi
from
Palatka, FL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital West
mi
from
Pembroke Pines, FL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital West
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Robert and Carol Weissman Cancer Center at Martin Health
mi
from
Stuart, FL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Robert and Carol Weissman Cancer Center at Martin Health
mi
from
Stuart, FL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
mi
from
Savannah, GA
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
mi
from
Savannah, GA
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Queen's Medical Center
mi
from
Honolulu, HI
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Queen's Medical Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
The Cancer Center of Hawaii-Liliha
mi
from
Honolulu, HI
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
The Cancer Center of Hawaii-Liliha
mi
from
Honolulu, HI
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Cancer Care Center-Boise
mi
from
Boise, ID
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Univ of Illinois
mi
from
Chicago, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Edward Hospital Cancer Center
mi
from
Naperville, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Edward Hospital Cancer Center
mi
from
Naperville, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Edward Hospital/Cancer Center?Plainfield
mi
from
Plainfield, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Edward Hospital/Cancer Center?Plainfield
mi
from
Plainfield, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Memorial Medical Center
mi
from
Springfield, IL
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Anderson Regional Hospital/Cancer Center
mi
from
Anderson, IN
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Anderson Regional Hospital/Cancer Center
mi
from
Anderson, IN
Click here to add this to my saved trials
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  12/31/1969
Radiation Oncology Associates PC
mi
from
Fort Wayne, IN
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 12/31/1969
Radiation Oncology Associates PC
mi
from
Fort Wayne, IN
Click here to add this to my saved trials